发明授权
US07348429B2 Process for purifying N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide(zaleplon) and crystalline forms of zaleplon accessible with the process
失效
纯化N- [3-(3-氰基吡唑并[1,5-a]嘧啶-7-基)苯基] -N-乙基乙酰胺(zaleplon)的方法和可通过该方法获得的扎来普隆的结晶形式
- 专利标题: Process for purifying N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide(zaleplon) and crystalline forms of zaleplon accessible with the process
- 专利标题(中): 纯化N- [3-(3-氰基吡唑并[1,5-a]嘧啶-7-基)苯基] -N-乙基乙酰胺(zaleplon)的方法和可通过该方法获得的扎来普隆的结晶形式
-
申请号: US10952151申请日: 2004-09-27
-
公开(公告)号: US07348429B2公开(公告)日: 2008-03-25
- 发明人: Erika Feher , Ferenc Korodi , Claude Singer , Erika Magyar
- 申请人: Erika Feher , Ferenc Korodi , Claude Singer , Erika Magyar
- 申请人地址: HU
- 专利权人: TEVA Gyógyszergyár Zártköruen Muködö Részvénytársaság
- 当前专利权人: TEVA Gyógyszergyár Zártköruen Muködö Részvénytársaság
- 当前专利权人地址: HU
- 代理机构: Kenyon & Kenyon LLP
- 主分类号: C07D487/04
- IPC分类号: C07D487/04 ; A61K31/519 ; G01N33/15
摘要:
Provided are novel Zaleplon crystalline Forms II, III, IV and V, which are useful for the treatment of insomnia. Also provided are processes for making Forms I, II, and V using precipitation methods.
公开/授权文献
信息查询